Press Releases

Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) NESS ZIONA, Israel – Oct. 10, 2023 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development...

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris’ long-standing and continued commitment toward addressing the unmet needs of the MS...

Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) PITTSBURGH, April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi...

The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo NESS ZIONA, Israel – Sep. 21, 2022 – Mapi...

Interim analysis of Phase IIa study of GA Depot in PPMS will be presented NESS ZIONA, Israel – May 31, 2022 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable...

NESS ZIONA, Israel – March 31, 2022 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that two...

NESS ZIONA, Israel – March 30, 2022 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that the...

DUBAI, UAE and Ness Ziona, Israel, October 21, 2021 – Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle...

Results for Glatiramer Acetate (GA) Depot Phase IIa study in patients with primary progressive multiple sclerosis, and novel anti-BMP for remyelination treatment in MS will be presented ECTRIMS 2021 Digital Experience will be held virtually Oct. 13-15, 2021  ...

Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center   NESS ZIONA, Israel – Dec. 21, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company,...

Facility in the Jerusalem Har-Hotzim technology park is built at the highest GMP standards; capability to provide reliable supply of COVID-19 vaccines, if approved   NESS ZIONA, Israel – Oct. 7, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage...

NESS ZIONA, Israel, September 30, 2020 -- Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today greets its partner, Zhejiang Jingxin Pharmaceutical Co Ltd.   To our friends and partners at Jingxin Pharma, On...

90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years Data suggest that GA Depot may also have potential as a primary progressive multiple sclerosis (PPMS) treatment   NESS...

NESS ZIONA, Israel, June 15, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced an additional $20 million investment from Mylan in support of continued Phase 3 clinical study progress to bring to market in the U.S. Glatiramer Acetate (GA) Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS). Glatiramer acetate, the active material of Copaxone^®, or its generic forms, is the most common treatment for RMS in the US. GA Depot is a long-acting depot formulation injection of glatiramer acetate administered once every four weeks, compared with the daily or thrice weekly regimen used with Copaxone^® or its generic forms…

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative solutions for neurological indications, announced today that the company will present recent advancements in its pipeline for treating MS at the leading MS conference, ECTRIMS 2019, which is being held in Stockholm, Sweden on September 11-13, 2019.

Sterile injectable facility will enable the supply of commercial needs as part of the agreement with Mylan. Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term lease agreement at the Har-Hotzvim Hi-Tech Park in Jerusalem for the establishment of a new sterile production plant for GA Depot injectable products…

Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the Israeli Ministry of the Economy to build a new sterile production plant for GA Depot injectable products. The approved financing plan is for a pioneering production plant for the manufacturing of a slow release formulation of Glatiramer Acetate (GA) (Copaxone^®) for treating multiple sclerosis.

Analyst Lunch and Live Webcast on Tuesday March 5th at 12 Noon ET NESS ZIONA, Israel – February 21, 2019 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its...

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co., Ltd. a publicly listed Chinese pharmaceutical company manufacturing products for neurological, cardiovascular, and digestive system indications. Jingxin is also a current shareholder of Mapi Pharma, following an initial $10 million investment in 2016.

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company will present two-year clinical data from its Phase II study of GA Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which will take place on October 10-12 in Berlin, Germany.

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial to support...

Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation of glatiramer acetate for multiple sclerosis (MS) on Tuesday, February 13th in New York City.

Mapi Pharma Ltd announced today that the first patient has been treated with GA Depot in the company’s Phase II study for primary progressive multiple sclerosis (PPMS). Glatiramer acetate, the active material of Copaxone^®, is the most common treatment for RRMS in the US. GA Depot is a long-acting depot formulation injection of glatiramer acetate administered once every four weeks rather than daily or thrice weekly as in the case of Copaxone^®.

Mapi Pharma Ltd., a fully integrated, clinical stage biopharmaceutical company, presented the Phase II results of its lead product Glatiramer Acetate (GA/Copaxone^®) Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) as late breaking news at the ECTRIMS-ACTRIMS meeting in Paris.

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

Mapi Pharma Ltd. announced today that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round that included participation by the company’s chairman and CEO Mr. Ehud Marom.

Mapi Pharma Ltd. announced today that the first patient was treated in the company’s Phase IIa study of GA Depot, in development as a treatment for relapsing remitting multiple sclerosis (RRMS).  Glatiramer Acetate is the active ingredient in Copaxone^®, the most common treatment for RRMS. GA Depot is a long-acting depot formulation injection of Glatiramer Acetate given once a month rather than daily or thrice weekly as in the case of Copaxone^®. 

Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company’s Glatiramer Acetate Depot has been extended until December 2030.

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment of moderate-to-severe acute pain.

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for a long acting depot formulation of glatiramer acetate.

Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets, announced today that it was granted a United States patent covering the process for the preparation of Fingolimod, a drug currently marketed by Novartis under the trade name Gilenya.